AMRX - Amneal Pharmaceuticals, Inc.

NYSE - NYSE Delayed Price. Currency in USD
6.90
+0.03 (+0.44%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close6.87
Open6.86
Bid0.00 x 1100
Ask0.00 x 2900
Day's Range6.77 - 7.01
52 Week Range6.77 - 24.48
Volume1,305,706
Avg. Volume998,132
Market Cap2.062B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barclays Has New Plays for Healthcare Fans
    SmarterAnalyst6 days ago

    Barclays Has New Plays for Healthcare Fans

    Investment banker Barclays announced it has initiated coverage of 20 U.S. specialty pharmaceuticals stocks.But which 20 stocks within this sector are we talking about today? They include generic drugs companies Mylan (MYL), which Barclays rates Overweight (i.e. 'buy') and Teva Pharmaceutical Industries (TEVA), which the analyst rates Underweight (i.e. 'sell'), as well as: * Amneal Pharmaceuticals (AMRX) * Endo International (ENDP) * Reddy's Laboratories (RDY) * and Mallinckrodt plc (MNK)Each of which is rated Equal weight (i.e. 'hold').Within the animal health sector (i.e. veterinary medicine), Barclays initiates coverage with Overweight ratings on Zoetis (ZTS) and Kindred Biosciences (KIN), but gives Phibro Animal Health Corporation (PAHC) an Underweight rating.Among developmental and commercial stage companies "with unique products & segments," Barclays has two 'sells' -- Allergan (AGN) and Evolus (EOLS) -- and one hold: Ligand Pharmaceuticals (LGND). As for Barclays' 'buy' ratings, it rates the following companies Overweight ratings: * AMAG Pharmaceuticals (AMAG) * Jazz Pharmaceuticals (JAZZ) * Osmotica Pharmaceuticals (OSMT) * Coherus BioSciences (CHRS) * Pacira BioSciences (PCRX) * Revance Therapeutics (RVNC) * Bausch Health Companies (BHC) * and Foamix Pharmaceuticals (FOMX)Today, we really only have time to glance at just one of these stocks: Rehovot, Israel-based Foamix.Foamix is a late clinical-stage specialty pharmaceutical company focusing on foam-based medications for the treatment of acne and rosacea. Foamix stands out in this report primarily by virtue of the extremely high hopes Barclays'  has for it, namely, valued at just $2.53 per share today, Barclays believes that within a year, Foamix stock will be selling for $10 -- a four-bagger in just one year.Why is Barclays so optimistic? As the analyst explains, Foamix is on the cusp of becoming a "commercial stage company" -- i.e. a company with actual revenue from sales, a rarity in small drugs stocks -- thanks to its topical Minocycline product for acne and rosacea. Designated "FMX-101" for acne treatment and "FMX-103" for rosacea, both these foam-based products "combine [the] proven efficacy of minocycline with a more tolerable side effect profile" says Barclays. From $3 million in annual revenue today, the banker predicts Foamix could do as much as $272 million in annual sales by 2025E.Considering that the entire company has a market cap of barely half that number -- $138 million -- today, Foamix at least seems to have earned its place on Barclays' list.Foamix has a few upcoming catalysts that could send its shares surging higher: * There is a scheduled PDUFA for FMX-101 on October 20, 2019. This is a key event for Foamix, as FMX-101 is its lead product in acne. * Foamix anticipates filing an NDA in mid-2019 for FMX-103 in moderate-to-severe papulopustular rosacea. * FCD-105 Phase II study initiation in mid-2019: FCD-105 is another pipeline product being evaluated in patients with acne and is a foam-based combination of minocycline and adapalene."We value Foamix on a DCF basis, assuming an 11.5% discount rate and a 3% terminal growth. We include risk adjusted pipeline values for both FMX-101 (90% probability of success) and FMX-103 (70% probability of success). We also assume base uptake of FMX-101, reaching 2025 risk-adj. sales of ~$200mm. This scenario yields a value of ~$10/share and serves as the basis for our price target," Barclays noted.Read more: Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now More recent articles from Smarter Analyst: * Village Farms (VFF) Has a Lot Going for It * Hexo Has Difficult Days Ahead, Analyst Says * Square (SQ) Growth Slowing, But Evercore Remains Bullish on the Stock * This Analyst Sticks with His Buy Rating on Aphria (APHA) Stock, But Trims Price Target

  • An Antitrust Lawsuit Could Cost Generic Pharmas Billions Of Dollars
    Investor's Business Daily25 days ago

    An Antitrust Lawsuit Could Cost Generic Pharmas Billions Of Dollars

    Teva Pharmaceutical and Mylan could be on the hook for billions in damages after a lawsuit accused pharmaceutical companies of colluding to fix generic drug prices, an analyst said Friday.

  • Need To Know: Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Insiders Have Been Selling Shares
    Simply Wall St.25 days ago

    Need To Know: Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Insiders Have Been Selling Shares

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

  • Amneal Pharmaceuticals, Inc. (AMRX) Q1 2019 Earnings Call Transcript
    Motley Foollast month

    Amneal Pharmaceuticals, Inc. (AMRX) Q1 2019 Earnings Call Transcript

    AMRX earnings call for the period ending March 31, 2019.

  • Why Amneal Pharmaceuticals Stock Is Cratering Today
    Motley Foollast month

    Why Amneal Pharmaceuticals Stock Is Cratering Today

    Investors were none too pleased with Amneal's first-quarter performance. Here's why.

  • Amneal Pharmaceuticals (AMRX) Misses Q1 Earnings Estimates
    Zackslast month

    Amneal Pharmaceuticals (AMRX) Misses Q1 Earnings Estimates

    Amneal (AMRX) delivered earnings and revenue surprises of -22.22% and 2.66%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Amneal: 1Q Earnings Snapshot

    The Bridgewater, New Jersey-based company said it had a loss of 37 cents per share. Earnings, adjusted for one-time gains and costs, were 14 cents per share. The results missed Wall Street expectations. ...

  • Here’s What Hedge Funds Think About Amneal Pharmaceuticals, Inc. (AMRX)
    Insider Monkey2 months ago

    Here’s What Hedge Funds Think About Amneal Pharmaceuticals, Inc. (AMRX)

    Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]

  • GuruFocus.com3 months ago

    Amneal Pharmaceuticals Inc (AMRX) President and CEO Robert A Stewart Bought $202,640 of Shares

    President and CEO of Amneal Pharmaceuticals Inc (NYSE:AMRX) Robert A Stewart bought 17,000 shares of AMRX on 03/12/2019 at an average price of $11.92 a share.

  • New Strong Sell Stocks for March 5th
    Zacks3 months ago

    New Strong Sell Stocks for March 5th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

  • GuruFocus.com4 months ago

    Amneal Pharmaceuticals Inc (AMRX) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Amneal Pharmaceuticals Inc (NYSE:AMRX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.

  • Amneal Pharmaceuticals (AMRX) Surges: Stock Moves 8.6% Higher
    Zacks4 months ago

    Amneal Pharmaceuticals (AMRX) Surges: Stock Moves 8.6% Higher

    Amneal Pharmaceuticals (AMRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

  • Amneal Pharmaceuticals, Inc. (AMRX) Q4 2018 Earnings Conference Call Transcript
    Motley Fool4 months ago

    Amneal Pharmaceuticals, Inc. (AMRX) Q4 2018 Earnings Conference Call Transcript

    AMRX earnings call for the period ending December 31, 2018.

  • Genentech files flurry of lawsuits to protect $100,000-a-year drug
    American City Business Journals4 months ago

    Genentech files flurry of lawsuits to protect $100,000-a-year drug

    Genentech bought InterMune and the Brisbane company's idiopathic pulmonary fibrosis drug Esbriet for more than $8 billion in fall 2014. Now it faces pressure from more than a dozen generic drug makers.

  • Does Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Have A Place In Your Portfolio?
    Simply Wall St.5 months ago

    Does Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Have A Place In Your Portfolio?

    This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at Amneal Pharmaceuticals, Inc.'s (NYSE:AMRX) P/E ratio and reflect Read More...

  • Hedge Funds Aren’t Crazy About Alta Mesa Resources, Inc. (AMR) Anymore
    Insider Monkey6 months ago

    Hedge Funds Aren’t Crazy About Alta Mesa Resources, Inc. (AMR) Anymore

    Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips on the charts, usually don’t make them change their opinion towards a company. This time it may be different. During the first 6 weeks of the fourth quarter we observed increased volatility and small-cap stocks underperformed […]

  • J&J Loses Appeal to Halt Generic Zytiga Launch, Stock Down
    Zacks7 months ago

    J&J Loses Appeal to Halt Generic Zytiga Launch, Stock Down

    A U.S. appeals court declines J&J's (JNJ) request to prevent the launch of generic versions of Zytiga. Stock down more than 3%.

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of AMRX.N earnings conference call or presentation 7-Nov-18 1:30pm GMT

    Q3 2018 Amneal Pharmaceuticals Inc Earnings Call

  • These Factors Make Amneal Pharmaceuticals Inc (NYSE:AMRX) An Interesting Investment
    Simply Wall St.7 months ago

    These Factors Make Amneal Pharmaceuticals Inc (NYSE:AMRX) An Interesting Investment

    Attractive stocks have exceptional fundamentals. In the case of Amneal Pharmaceuticals Inc (NYSE:AMRX), there’s is a company with a buoyant growth outlook, which has not yet been factored into the Read More...

  • Associated Press7 months ago

    Amneal: 3Q Earnings Snapshot

    On a per-share basis, the Bridgewater, New Jersey-based company said it had profit of 5 cents. Earnings, adjusted for one-time gains and costs, came to 28 cents per share. The results surpassed Wall Street ...

  • Investor's Business Daily8 months ago

    Knock Offs Loom For J&J's Blockbuster — Why An Analyst Is Still Bullish

    Two generic drugmakers can knock off Johnson & Johnson's blockbuster cancer treatment, Zytiga, as soon as Wednesday — but an analyst remained bullish Monday on the Dow Jones stock.

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of AMRX.N earnings conference call or presentation 9-Aug-18 12:30pm GMT

    Q2 2018 Amneal Pharmaceuticals Inc Earnings Call

  • Opioid antidote inventor: We're in the 'next phase of this opioid crisis'
    Yahoo Finance8 months ago

    Opioid antidote inventor: We're in the 'next phase of this opioid crisis'

    "We are now in the next phase of this opioid crisis, where the majority of deaths arise from fentanyl.”

  • Simply Wall St.9 months ago

    Does Amneal Pharmaceuticals Inc’s (NYSE:AMRX) PE Ratio Signal A Buying Opportunity?

    This analysis is intended to introduce important early concepts to people who are starting to invest and want to learn about the link between company’s fundamentals and stock market performance. Read More...

  • Here's Why Amneal Pharmaceuticals Inc. Rose as Much as 13.4% Today
    Motley Fool10 months ago

    Here's Why Amneal Pharmaceuticals Inc. Rose as Much as 13.4% Today

    The company snagged a huge supply contract with Jerome Stevens Pharmaceuticals.